The 2023 edition of the American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium will take place from February 16 to February 18, 2023 in Moscone West, San Francisco. ASCO-GU 2023 showcases ground-breaking research regarding the diagnosis and treatment of GU malignancies. Over the course of the three conference days, 800+ abstracts will be presented in a hybrid format, using both in-person and online sessions.
Most Highly Anticipated Abstracts
ASCO-GU has released the abstract titles as of January 10th. Below are some of the most highly anticipated abstracts among healthcare professionals.
- Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).
PROpel, NCT03732820 | AstraZeneca (Abiraterone, Olaparib)
Session Type: General Session
Indication: First-Line Metastatic Castration-Resistant Prostate Cancer
Author: Noel Clarke
- Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
KEYNOTE 921, NCT03834506, | Merck (Docetaxel, Pembrolizumab)
Session Type: Poster Session
Indication: Metastatic Castration-Resistant Prostate Cancer
Author: Daniel Petrylak
- Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
CheckMate 9ER, NCT03141177 | Bristol-Myers Squibb (Cabozantinib, Nivolumab)
Session Type: Oral Session
Indication: First-Line Advanced Renal Cell Carcinoma
Author: Mauricio Burotto
- Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
TRITON3, NCT02975934 | Clovis Oncology (Rucaparib)
Session Type: Oral Session
Indication: Metastatic Castration-Resistant Prostate Cancer
Author: Alan Bryce
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
JAVELIN Bladder 100, NCT02603432 | Pfizer (Avelumab)
Session Type: Poster Session
Indication: First-Line Advanced Urothelial Carcinoma
Author: Srikala Sridhar
Drugs in Focus: Additional High-Profile Abstracts
Here are a few additional abstracts of interest for significant FDA-approved medications.
Cabozantinib in combination with Nivolumab
- Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
CheckMate 9ER, NCT03141177 | Bristol-Myers Squibb
Session Type: Oral Session
Indication: First-Line Advanced Renal Cell Carcinoma
Author: Mauricio Burotto
- CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.
CaboCombo, NCT05361434 | Ipsen
Session Type: Poster Session
Indication: Advanced Renal Cell Carcinoma
Author: Philippe Barthelemy
- Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).
CheckMate 9ER, NCT03141177 | Bristol-Myers Squibb
Session Type: Rapid Abstract Session
Indication: Advanced Renal Cell Carcinoma
Author: Toni Choueiri
Avelumab
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
JAVELIN Bladder 100, NCT02603432 | Pfizer
Session Type: Poster Session
Indication: First-Line Advanced Urothelial Carcinoma
Author: Srikala Sridhar
- Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
AVENANCE, NCT04822350 | Merck and Pfizer
Session Type: Poster Session
Indication: First-line Advanced Urothelial Carcinoma
Author: Philippe Barthelemy
- Activity and tolerability of maintenance avelumab (AVE) immunotherapy after first-line platinum-based polychemotherapy in patients (pts) with locally advanced or metastatic squamous cell penile carcinoma: Initial results of PULSE study.
PULSE, NCT03774901 | Pfizer
Session Type: Poster Session
Indication : Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
Author: Antoine Thiery-Vuillemin
Gemcitabine, Cisplatin plus Nivolumab
- Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).
HCRN GU 16-257, NCT03558087 | Bristol-Myers Squibb
Session Type: Poster Session
Indication : Muscle Invasive Bladder Cancer
Author: Matt Galsky
- Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.
BLASST-1, NCT03294304 | Veracyte
Session Type: Poster Session
Indication : Muscle Invasive Bladder Cancer
Author: Shilpa Gupta
A more comprehensive overview will be published once the abstracts are released.
